Drug Formulation and Manufacturing Contract II (DFMC)
ID: NIHOD20250424WILLIAMETTIType: Sources Sought
Overview

Buyer

HEALTH AND HUMAN SERVICES, DEPARTMENT OFNATIONAL INSTITUTES OF HEALTHNATIONAL INSTITUTES OF HEALTH OLAOBETHESDA, MD, 20892, USA

NAICS

Pharmaceutical Preparation Manufacturing (325412)

PSC

MISCELLANEOUS CHEMICAL SPECIALTIES (6850)

Set Aside

Partial Small Business Set-Aside (FAR 19.5) (SBP)

Original Source

https://sam.gov/opp/fc17bbc913114ae1974f0ac1a2b3b26a/view
Timeline
    Description

    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), is seeking qualified vendors for the Drug Formulation and Manufacturing Contract II (DFMC II), aimed at facilitating the manufacturing and documentation processes for investigational drug products. The contract will involve multiple award Indefinite Delivery/Indefinite Quantity (ID/IQ) contracts, focusing on the development of dosage forms for small molecule drug candidates intended for clinical trials and preclinical studies, while ensuring compliance with Good Manufacturing Practices (cGMP) and FDA documentation standards. This initiative is critical for maintaining high standards in drug development and research support, with the goal of centralizing contracts across NIH to enhance efficiency. Interested parties must submit their qualifications, including a capability statement and past performance examples, by May 19, 2025, to Dr. William H. M. Etti at William.Etti@nih.gov.

    Point(s) of Contact
    Dr. William H. M. Etti
    (301) 402-4422
    William.Etti@nih.gov
    Files
    Title
    Posted
    New DFMC SOW_DRAFT 01Feb25 clean.docx
    The National Institutes of Health (NIH) is initiating the Drug Formulation and Manufacturing Contracts II (DFMC II) to facilitate the manufacturing and documentation processes for investigational drug products under the Office of Research Support and Compliance (ORSC). The aim is to develop dosage forms of small molecule drug candidates for clinical trials and preclinical studies. DFMC II comprises multiple award Indefinite Delivery/Indefinite Quantity (ID/IQ) contracts, succeeding the previous DFMC set to end in late 2024. Responsibilities encompass compliance with Good Manufacturing Practices (cGMP) and the preparation of necessary documentation acceptable to the FDA. Key activities include technical support for drug product development, formulation manufacturing studies, stability assessments, and comprehensive supply chain management—covering packaging, labeling, storage, and distribution. The contractor must maintain vendor qualifications and adhere to stringent regulatory standards to guarantee product safety, quality, and compliance throughout the contract duration. Furthermore, the contractor is expected to provide periodic reports detailing project progress, regulatory compliance, and other key operational metrics, while maintaining strict confidentiality of sensitive data. This RFP underscores the NIH's commitment to upholding high standards in drug development and research support while streamlining procurement processes for investigational products.
    Lifecycle
    Title
    Type
    Drug Manufacturing and Formulation Contract II
    Currently viewing
    Sources Sought
    Similar Opportunities
    NCI OA Special Notice of Subcontract Opportunity at the Frederick National Laboratory for Cancer Research
    Health And Human Services, Department Of
    The National Institutes of Health (NIH), through the National Cancer Institute (NCI), is seeking information regarding an Electronic Document Management System (EDMS) for the Frederick National Laboratory for Cancer Research (FNLCR), which is operated by Leidos Biomedical Research, Inc. The EDMS aims to centralize and enhance the control and maintenance of construction project documentation for the Facilities, Maintenance, and Engineering (FME) Directorate, thereby improving collaboration among project teams and facilitating reporting for lessons learned and metrics. This initiative is crucial for streamlining documentation processes and may expand to other directorates in the future. Interested parties should submit their responses by January 9, 2026, and direct any inquiries to Cody Wenner at cody.wenner@nih.gov.
    Department of Defense Pharmacy Uniform Formulary Blanket Purchase Agreement/Uniform Formulary Additional Discount Program
    Dept Of Defense
    The Department of Defense, through the Defense Health Agency, is soliciting quotes for the Pharmacy Uniform Formulary Blanket Purchase Agreement and the Uniform Formulary Additional Discount Program, aimed at establishing an effective pharmacy benefits program for the Military Health System. This procurement involves the evaluation and selection of pharmaceutical agents based on their clinical and cost-effectiveness, with a focus on newly approved drugs that will be reviewed by the Pharmacy and Therapeutics Committee in February 2025. Interested vendors must submit their pricing information, including National Drug Codes (NDCs), by December 19, 2024, and are encouraged to participate in a pre-quotation teleconference on December 4, 2024. For further inquiries, vendors can contact Tracy Banks at tracy.e.banks2.civ@mail.mil or Julia Trang at julia.n.trang.civ@health.mil.
    PREVENT Cancer Preclinical Drug Development Program
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), is seeking to increase the programmatic ceiling for several contracts under the PREVENT Cancer Preclinical Drug Development Program. This initiative aims to enhance funding for ongoing contracts numbered 75N91019D00012 through 75N91019D00026, which are focused on health research and development services critical to advancing cancer treatment options. The adjustments to the contract values are essential for supporting continued research efforts in the field of cancer prevention and treatment. For further inquiries, interested parties can contact Rachel Turk at rachel.turk@nih.gov.
    Inflammatory and Vascular Diseases Scientific Support
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), is seeking to award a contract for Inflammatory and Vascular Diseases Scientific Support to Exonova Biosciences. The procurement aims to secure the services of a highly qualified scientist with extensive expertise in immunology and hereditary autoinflammatory diseases, who will contribute to the NIH's Biomedical and Metabolic Imaging Branch's research initiatives. This contract is crucial for advancing understanding in the fields of inflammation and vascular biology, particularly in relation to metabolic disorders, and is set to commence on January 1, 2026, with a performance period extending through December 31, 2026. Interested parties must respond by December 15, 2025, and can direct inquiries to Kimesha Leake at Kimesha.leake@nih.gov.
    Metformin HCL
    Dept Of Defense
    Presolicitation DEPT OF DEFENSE DEFENSE LOGISTICS AGENCY is planning to issue a national requirements contract for Metformin HCL ER. The contract will establish a national supply source to provide Metformin HCL ER Tablets in various quantities and bottle sizes. This will be an unrestricted and fully competitive acquisition. The contract will be a firm-fixed price, requirements type contract with a one year base and four one year options. The items will be purchased by Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers through the DLA and VA prime vendor programs. The solicitation will be posted on DLA Bid Board System (DIBBS) and Sam.gov. Interested parties should contact Christopher Newman for any questions/comments. The projected solicitation date is August 2021.
    Notice of Intent to Sole Source 2 sets of QX200 ddPCR Systems
    Health And Human Services, Department Of
    The National Institutes of Health (NIH), specifically the Clinical Center (CC), intends to negotiate a sole-source contract for the renewal of maintenance services for two QX200 AutoDG ddPCR Systems from Bio-Rad Laboratories. This five-year service contract, valued at $151,494, is essential for the ongoing maintenance and support of these systems, which are critical for droplet digital PCR (ddPCR) vector copy number detection and gene modification efficiency testing on clinical cellular products. The contract ensures compliance with FDA regulations and is vital for patient care testing, as failure to secure these services could adversely affect patient safety. Interested parties may submit capability statements by December 18, 2025, to valerie.gregorio@nih.gov, referencing NOI-CC-26-000112.
    Support for Evaluating and Conducting Computational and Alternative Toxicological Methods for the National Institute of Environmental Health Sciences
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institute of Environmental Health Sciences (NIEHS), is seeking proposals from small businesses to support the evaluation and conduct of computational and alternative toxicological methods. The objective of this procurement is to assist NIEHS in chemical hazard and risk assessment while minimizing the use of animal testing, focusing on areas such as population variability, developmental neurotoxicity, and carcinogenicity. This contract, which is a Cost-Plus-Fixed-Fee type, has a base period of performance from June 1, 2026, to May 31, 2027, with nine additional one-year options and a potential six-month extension. Proposals are due by December 19, 2025, and must be submitted electronically via the NIH eCPS website; interested parties can contact Jason Williams at jason.williams2@nih.gov or Lisa Schaupp at lisa.schaupp@nih.gov for further information.
    GraphPad Prism Subscription Renewal
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), is seeking to renew a contract for 500 subscriptions of GraphPad Prism software, which is critical for biostatistical analysis and scientific graphing. This non-competitive procurement is justified under the Federal Acquisition Regulation (FAR) due to GraphPad Software, LLC being the sole provider of the software, with the renewal period set from April 8, 2025, to April 7, 2026. GraphPad Prism is widely utilized by research institutions and pharmaceutical companies, ensuring the accuracy and efficiency of scientific data analysis within the NIH. Interested vendors may express their capabilities, but the government retains discretion over competitive offers, with the total contract value not exceeding $250,000. For inquiries, contact Verne L. Griffin at verne.griffin@nih.gov or 301-594-7730, or Michael L. Falzone at michael.falzone@nih.gov or 301-827-1873.
    KNIME Data Science Platform Renewal
    Health And Human Services, Department Of
    The National Institute of Environmental Health Sciences (NIEHS), part of the Department of Health and Human Services, intends to negotiate a sole source contract for the renewal of the KNIME Data Science Platform. This procurement involves a 12-month license for KNIME Business Hub products, which are uniquely suited to meet the specific software requirements of the NIEHS. The software is critical for data science applications within the agency, and the government has determined that only KNIME INC can fulfill this need. Interested parties that believe they can meet these requirements may submit a capability statement to Joseph Williams at joseph.williams2@nih.gov by December 17, 2025, at 12:00 PM EST, although this is not a solicitation for quotes.
    FY26 FDA Broad Agency Announcement (BAA) for Advanced Research and Development of Regulatory Science
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the Food and Drug Administration (FDA), is soliciting proposals through the FY26 Broad Agency Announcement (BAA) for advanced research and development in regulatory science. This opportunity aims to acquire basic and applied research that supports regulatory science and innovation, focusing on areas such as New Approach Methodologies, Advanced Manufacturing, and Clinical Outcome Assessments, among others. The FDA's initiative is crucial for enhancing scientific knowledge that aids in protecting and promoting public health, particularly for underrepresented populations and in reducing animal testing. Interested parties, including small businesses and academic institutions, are encouraged to submit proposals by February 24, 2026, and can reach out to Ian Weiss at Ian.Weiss@fda.hhs.gov or by phone at 301-796-5728 for further information.